PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY APPLICATION
Market segmentation by application
Comparison by application
Oral - Market size and forecast 2018-2023
Topical - Market size and forecast 2018-2023
Other RoA - Market size and forecast 2018-2023
Market opportunity by application

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
Market drivers
Market challenges

PART 12: MARKET TRENDS
Application of novel technologies for PDE inhibitors development
Growing geriatric population
Rising burden of chronic diseases

PART 13: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario

PART 14: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Bayer AG
Eli Lilly and Co.
GlaxoSmithKline Plc
Pfizer Inc.
Vivus Inc.

PART 15: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
Exhibit 1: Global pharmaceuticals market
Exhibit 2: Segments of global pharmaceuticals market
Exhibit 3: Market characteristics
Exhibit 4: Market segments
Exhibit 5: Some of the commercially available PDE inhibitors
Exhibit 6: Disease targets for different PDE inhibitors
Exhibit 7: Market definition - Inclusions and exclusions checklist
Exhibit 8: Market size 2018
Exhibit 9: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Some of the phase III clinical trials of PDE inhibitors
Exhibit 20: Application - Market share 2018-2023 (%)
Exhibit 21: Comparison by application
Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Advantages of tablet dosage form
Exhibit 24: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 25: Topical - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Topical - Year-over-year growth 2019-2023 (%)
Exhibit 27: Other RoA - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Other RoA - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by application
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Role of PDE5 inhibitors in ED
Exhibit 48: Sales of PDE5 inhibitors after the launch of generics ($ millions)
Exhibit 49: Impact of drivers and challenges
Exhibit 50: CDC statistics about chronic diseases in geriatric population in the US over the past few years
Exhibit 51: Geriatric population scenario in the US
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Bayer AG - Vendor overview
Exhibit 58: Bayer AG - Product segments
Exhibit 59: Bayer AG - Organizational developments
Exhibit 60: Bayer AG - Geographic focus
Exhibit 61: Bayer AG - Segment focus
Exhibit 62: Bayer AG - Key offerings
Exhibit 63: Bayer AG - Key customers
Exhibit 64: Eli Lilly and Co. - Vendor overview
Exhibit 65: Eli Lilly and Co. - Business segments
Exhibit 66: Eli Lilly and Co. - Organizational developments
Exhibit 67: Eli Lilly and Co. - Geographic focus
Exhibit 68: Eli Lilly and Co. - Segment focus
Exhibit 69: Eli Lilly and Co. - Key offerings
Exhibit 70: Eli Lilly and Co. - Key customers
Exhibit 71: GlaxoSmithKline Plc - Vendor overview
Exhibit 72: GlaxoSmithKline Plc - Business segments
Exhibit 73: GlaxoSmithKline Plc - Organizational developments
Exhibit 74: GlaxoSmithKline Plc - Geographic focus
Exhibit 75: GlaxoSmithKline Plc - Segment focus
Exhibit 76: GlaxoSmithKline Plc - Key offerings
Exhibit 77: GlaxoSmithKline Plc - Key customers
Exhibit 78: Pfizer Inc. - Vendor overview
Exhibit 79: Pfizer Inc. - Business segments
Exhibit 80: Pfizer Inc. - Organizational developments
Exhibit 81: Pfizer Inc. - Geographic focus
Exhibit 82: Pfizer Inc. - Segment focus
Exhibit 83: Pfizer Inc. - Key offerings
Exhibit 84: Pfizer Inc. - Key customers
Exhibit 85: Vivus Inc. - Vendor overview
Exhibit 86: Vivus Inc. - Business segments
Exhibit 87: Vivus Inc. - Organizational developments
Exhibit 88: Vivus Inc. - Geographic focus
Exhibit 89: Vivus Inc. - Key offerings
Exhibit 90: Vivus Inc. - Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: Definition of market positioning of vendors

Companies Mentioned
• Bayer AG
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Pfizer Inc.
• Vivus Inc.